 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| 27T51 / Regeneron
Enrollment open, CAR T-Cell Therapy, Immune cell: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (clinicaltrials.gov) - Aug 7, 2024
P1, N=90, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting
- ||| 27T51 / Regeneron
New P1 trial, CAR T-Cell Therapy, Immune cell: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (clinicaltrials.gov) - Jun 21, 2024
P1, N=90, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals